TSE:RVX Resverlogix (RVX) Stock Price, News & Analysis C$0.05 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's RangeC$0.05▼C$0.0550-Day RangeC$0.05▼C$0.0652-Week RangeC$0.04▼C$0.11Volume1,000 shsAverage Volume37,021 shsMarket CapitalizationC$13.74 millionP/E RatioN/ADividend Yield7.02%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesStock AnalysisChartCompetitorsEarningsHeadlinesInsider Trades Get Resverlogix alerts: Email Address Ad WealthPressThis TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.But I can promise that you’ll see all the details for yourself here. About Resverlogix Stock (TSE:RVX)Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.Read More RVX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVX Stock News HeadlinesJuly 25 at 8:57 AM | theglobeandmail.comClosing Bell: Resverlogix Corp flat on Wednesday (RVX)May 28, 2024 | finance.yahoo.comResverlogix Announces Updated Annual and Special Meeting of ShareholdersJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.May 16, 2024 | finance.yahoo.comResverlogix Corp. (RVX.TO)May 13, 2024 | finance.yahoo.comResverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion PrivilegesFebruary 21, 2024 | finance.yahoo.comResverlogix Announces Change to Its Board of DirectorsJanuary 11, 2024 | finance.yahoo.comResverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic BenefitsJanuary 4, 2024 | theglobeandmail.comClosing Bell: Resverlogix Corp flat on Tuesday (RVX)July 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.December 19, 2023 | investing.comResverlogix Corp. (RVX) Earnings Dates & ReportsNovember 18, 2023 | morningstar.comResverlogix Corp RVXCFNovember 1, 2023 | morningstar.comResverlogix Corp RVXOctober 18, 2023 | theglobeandmail.comResverlogix: Top 10 Undervalued Healthcare Sector Stocks on TSX (RVX)October 4, 2023 | finanznachrichten.deResverlogix Corp.: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular DystrophyOctober 4, 2023 | finance.yahoo.comResverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular DystrophySeptember 26, 2023 | finance.yahoo.comAtherosclerotic Cardiovascular Disease Market to Observe Impressive Growth at a CAGR of 2.2% by 2032, Predicts DelveInsightAugust 29, 2023 | finance.yahoo.comResverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 DiabetesAugust 24, 2023 | theglobeandmail.comClosing Bell: Resverlogix Corp up on Wednesday (RVX)See More Headlines Receive RVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Resverlogix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today7/26/2024Next Earnings (Estimated)8/09/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:RVX CUSIPN/A CIKN/A Webwww.resverlogix.com Phone+1-403-2549252FaxN/AEmployees19Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-16,740,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-44.23% Debt Debt-to-Equity RatioN/A Current Ratio0.02 Quick Ratio0.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.00 per share Price / Cash Flow132.50 Book ValueC($0.27) per share Price / Book-0.19Miscellaneous Outstanding Shares274,820,000Free FloatN/AMarket CapC$13.74 million OptionableNot Optionable Beta0.69 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Donald J. McCaffreyCo-Founder, Chairman, President, CEO & SecretaryMr. Aaron Bradley Cann C.A.CPA, CBV, Chief Financial OfficerDr. Ewelina Kulikowski Ph.D.Chief Scientific OfficerDr. Michael Sweeney M.D. (Age 63)Senior Vice President of Clinical Development Comp: $511.56kSarah ZapotichnyDirector of Investor Relations & Corporate CommunicationsKey CompetitorsHelix BioPharmaTSE:HBPEmerald Health TherapeuticsCVE:EMHCovalon TechnologiesCVE:COVProMIS NeurosciencesTSE:PMNSmall PharmaCVE:DMTView All Competitors RVX Stock Analysis - Frequently Asked Questions How have RVX shares performed this year? Resverlogix's stock was trading at C$0.07 at the beginning of the year. Since then, RVX stock has decreased by 28.6% and is now trading at C$0.05. View the best growth stocks for 2024 here. How do I buy shares of Resverlogix? Shares of RVX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of Resverlogix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Resverlogix investors own include ProMetic Life Sciences (PLI), Aptose Biosciences (APTO), Oncolytics Biotech (ONC), Radient Technologies (RTI), VentriPoint Diagnostics (VPT) and Endocyte (ECYT). This page (TSE:RVX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Resverlogix Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Resverlogix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
